Study details
Enrolling now
Lebrikizumab Trial for Atopic Dermatitis
Johann E Gudjonsson MD PhD
NCT IDNCT06906497ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
48
Study length
about 2.1 years
Ages
18+
Locations
2 sites in CA, MI
About this study
Researchers are testing a treatment called lebrikizumab for moderate-to-severe atopic dermatitis. The trial will collect health information and samples to see if the drug improves skin conditions over time.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take lebrikizumab
PhasePhase 4
Druglebrikizumab
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
lebrikizumab
Endpoints
Secondary: Clinical response as assessed using the Peak Pruritus Numerical Rating Scale (NRS) (Pruitis NRS)
Body systems
Dermatology